drug · small molecule
pirtobrutinib
Marketedupdated 2mo agoby Eli Lilly and Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 3 investigational indications.
targets
Tyrosine-protein kinase BTK
all catalysts(0)
nothing on the calendar yet
Trials studying pirtobrutinib
- phase4A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- phase3A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- phase3A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- phase2Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
- phase3ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- phase3Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- phase2Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
- phase2Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 27, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Sep 14, 2041formulationUS 12109193
- Sep 14, 2041formulationUS 12109193
- Jul 29, 2039formulationUS 12268666
- Jul 29, 2039formulationUS 12268666
- Dec 16, 2036compositionUS 10342780
- Dec 16, 2036compositionUS 10342780
- Dec 16, 2036method-of-use (U-4362)US 10464905
- Dec 16, 2036method-of-use (U-4362)US 10464905
- Dec 16, 2036compositionUS 10695323
- Dec 16, 2036compositionUS 10695323
- Dec 16, 2036method-of-use (U-4362)US 10918622
- Dec 16, 2036method-of-use (U-4362)US 10918622
- Dec 16, 2036compositionUS 12220401
- Dec 16, 2036compositionUS 12220401
FDA exclusivities (8)
- Dec 1, 2030ODE-451Orphan Drug (7y)4.4y
- Dec 1, 2030ODE-451Orphan Drug (7y)4.4y
- Jan 27, 2030ODE-424Orphan Drug (7y)3.5y
- Jan 27, 2030ODE-424Orphan Drug (7y)3.5y
- Dec 2, 2028I-981Indication (3y)2.4y
- Dec 2, 2028I-981Indication (3y)2.4y
- Jan 27, 2028NCENew Chemical Entity (5y)1.5y
- Jan 27, 2028NCENew Chemical Entity (5y)1.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 45m ago
Found something off?
comments(0)
5-min edit window · permanent after that